New treatment approach for prostate cancer using peptoid molecules
Peptoid conjugates targeting prostate cancer
This study is exploring a new treatment for advanced prostate cancer using special molecules that can help fight cancer cells that don't respond to regular therapies, and it aims to find out how well these molecules work in boosting the body's immune response to improve patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10812127 on NIH RePORTER |
What this research studies
This research investigates a novel method to combat prostate cancer by using specially designed molecules called multivalent peptoid conjugates (MPCs) that target the androgen receptor. These MPCs are engineered to resist breakdown in the body, allowing them to effectively inhibit the growth of prostate cancer cells that have become resistant to standard treatments like enzalutamide. The study will analyze how these peptoids interact with cancer cells and promote immune responses to enhance treatment effectiveness. Patients may benefit from a new therapeutic option that could improve outcomes for those with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who have shown resistance to standard anti-androgen treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone anti-androgen therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with prostate cancer that is resistant to current therapies.
How similar studies have performed: Previous research has shown promise in using similar approaches to target cancer cells, indicating potential for success with this novel treatment strategy.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Garabedian, Michael J. — New York University School of Medicine
- Study coordinator: Garabedian, Michael J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.